Adcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedLC
Logos Capital
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $325M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed